226 related articles for article (PubMed ID: 38355513)
1. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Zhou J; Zheng Y; Xu B; Long S; Zhu LE; Liu Y; Li C; Zhang Y; Liu M; Wu X
BMC Med; 2024 Feb; 22(1):65. PubMed ID: 38355513
[TBL] [Abstract][Full Text] [Related]
2. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis.
Guirguis A; Chiappini S; Papanti P GD; Vickers-Smith R; Harris D; Corkery JM; Arillotta D; Floresta G; Martinotti G; Schifano F
Eur Neuropsychopharmacol; 2024 May; 82():82-91. PubMed ID: 38508100
[TBL] [Abstract][Full Text] [Related]
3. Postmarket safety profile of suicide/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis.
Chen C; Zhou R; Fu F; Xiao J
Eur Psychiatry; 2023 Nov; 66(1):e99. PubMed ID: 38031404
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide 1 receptor agonists and the potential risk of pancreatic carcinoma: a pharmacovigilance study using the FDA Adverse Event Reporting System and literature visualization analysis.
Cao M; Pan C; Tian Y; Wang L; Zhao Z; Zhu B
Int J Clin Pharm; 2023 Jun; 45(3):689-697. PubMed ID: 36977858
[TBL] [Abstract][Full Text] [Related]
5. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS).
McIntyre RS; Mansur RB; Rosenblat JD; Kwan ATH
Expert Opin Drug Saf; 2024 Jan; 23(1):47-55. PubMed ID: 38087976
[TBL] [Abstract][Full Text] [Related]
6. Safety of Glucagon-Like Peptide-1 Receptor Agonists: A Real-World Study Based on the US FDA Adverse Event Reporting System Database.
Wu T; Zhang Y; Shi Y; Yu K; Zhao M; Liu S; Zhao Z
Clin Drug Investig; 2022 Nov; 42(11):965-975. PubMed ID: 36175609
[TBL] [Abstract][Full Text] [Related]
7. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
Liu L; Chen J; Wang L; Chen C; Chen L
Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
9. Psychiatric adverse events associated with GLP-1 receptor agonists: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System database.
Chen W; Cai P; Zou W; Fu Z
Front Endocrinol (Lausanne); 2024; 15():1330936. PubMed ID: 38390214
[TBL] [Abstract][Full Text] [Related]
10. Difference in Gastrointestinal Risk Associated with Use of GLP-1 Receptor Agonists: A Real-World Pharmacovigilance Study.
Zhou Y; Chen M; Liu L; Chen Z
Diabetes Metab Syndr Obes; 2022; 15():155-163. PubMed ID: 35046686
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
Pinelli NR; Hurren KM
Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
[TBL] [Abstract][Full Text] [Related]
12. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists.
Madsbad S
Diabetes Obes Metab; 2016 Apr; 18(4):317-32. PubMed ID: 26511102
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.
Xie Z; Hu J; Gu H; Li M; Chen J
Front Endocrinol (Lausanne); 2023; 14():1244432. PubMed ID: 37701904
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
Yuan S; Wu Y
Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemia following the use of glucagon-like peptide-1 receptor agonists: a real-world analysis of post-marketing surveillance data.
Zhao Z; Tang Y; Hu Y; Zhu H; Chen X; Zhao B
Ann Transl Med; 2021 Sep; 9(18):1482. PubMed ID: 34734034
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like Peptide-1 Receptor Agonists and Suicidal Ideation: Analysis of Real-Word Data Collected in the European Pharmacovigilance Database.
Ruggiero R; Mascolo A; Spezzaferri A; Carpentieri C; Torella D; Sportiello L; Rossi F; Paolisso G; Capuano A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399362
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System.
Fadini GP; Sarangdhar M; Avogaro A
BMJ Open Diabetes Res Care; 2018; 6(1):e000475. PubMed ID: 29449951
[TBL] [Abstract][Full Text] [Related]
18. Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.
Dong S; Sun C
Front Endocrinol (Lausanne); 2022; 13():1032199. PubMed ID: 36583004
[TBL] [Abstract][Full Text] [Related]
19. Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis.
Zaccardi F; Htike ZZ; Webb DR; Khunti K; Davies MJ
Ann Intern Med; 2016 Jan; 164(2):102-13. PubMed ID: 26642233
[TBL] [Abstract][Full Text] [Related]
20. GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.
Triplitt C; Solis-Herrera C
Diabetes Educ; 2015 Dec; 41(1 Suppl):32S-46S. PubMed ID: 26450217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
